$5.50
0.18%
Nasdaq, Aug 29, 10:06 pm CET
ISIN
US8106481059
Symbol
SCPH

scPharmaceuticals, Inc. Stock price

$5.50
+0.05 0.92% 1M
+2.22 67.68% 6M
+1.96 55.37% YTD
+0.46 9.13% 1Y
-0.26 4.51% 3Y
-3.06 35.75% 5Y
-8.60 60.99% 10Y
-8.60 60.99% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.01 0.18%
ISIN
US8106481059
Symbol
SCPH
Industry

Key metrics

Basic
Market capitalization
$293.1m
Enterprise Value
$303.5m
Net debt
$10.4m
Cash
$40.8m
Shares outstanding
53.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.9 | 3.9
EV/Sales
6.1 | 4.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
12.4%
Return on Equity
-639.3%
ROCE
-133.0%
ROIC
-
Debt/Equity
-2.4
Financials (TTM | estimate)
Revenue
$50.0m | $75.9m
EBITDA
$-79.4m | $-48.6m
EBIT
$-79.6m | $-53.7m
Net Income
$-91.7m | $-58.0m
Free Cash Flow
$-65.9m
Growth (TTM | estimate)
Revenue
107.8% | 109.0%
EBITDA
-31.7% | 24.9%
EBIT
-31.8% | 17.1%
Net Income
-51.3% | 31.9%
Free Cash Flow
1.1%
Margin (TTM | estimate)
Gross
68.5%
EBITDA
-158.9% | -64.0%
EBIT
-159.2%
Net
-183.6% | -76.4%
Free Cash Flow
-131.8%
More
EPS
$-1.7
FCF per Share
$-1.2
Short interest
2.9%
Employees
163
Rev per Employee
$220.0k
Show more

Is scPharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

scPharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a scPharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a scPharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from scPharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
50 50
108% 108%
100%
- Direct Costs 16 16
127% 127%
32%
34 34
100% 100%
68%
- Selling and Administrative Expenses 85 85
31% 31%
171%
- Research and Development Expense 15 15
27% 27%
31%
-79 -79
32% 32%
-159%
- Depreciation and Amortization 0.17 0.17
42% 42%
0%
EBIT (Operating Income) EBIT -80 -80
32% 32%
-159%
Net Profit -92 -92
51% 51%
-184%

In millions USD.

Don't miss a Thing! We will send you all news about scPharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

scPharmaceuticals, Inc. Stock News

Neutral
Business Wire
5 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per...
Neutral
GlobeNewsWire
6 days ago
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
GlobeNewsWire
7 days ago
MONSEY, N.Y., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. (Nasdaq: SCPH) (“SCPH”) to MannKind Corporation (“MannKind”) for $5.35 per share in cash, plus one non-tradable contingent value right (“CVR”) per share offering milestone-based payments of up to $1.00 per share.
More scPharmaceuticals, Inc. News

Company Profile

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Head office United States
CEO John Tucker
Employees 163
Founded 2013
Website www.scpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today